Millennium Management’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $17.2M | Buy |
3,660,190
+3,370,537
| +1,164% | +$17.1M | 0.01% | 1673 |
|
|
2025
Q4 | $1.23M | Sell |
289,653
-1,097,210
| -79% | -$4.17M | ﹤0.01% | 4334 |
|
|
2025
Q3 | $4.42M | Buy |
1,386,863
+1,153,524
| +494% | +$2.6M | ﹤0.01% | 3265 |
|
|
2025
Q2 | $530K | Sell |
233,339
-2,592,937
| -92% | -$4.18M | ﹤0.01% | 4870 |
|
|
2025
Q1 | $1.8M | Sell |
2,826,276
-394,736
| -12% | -$306K | ﹤0.01% | 3881 |
|
|
2024
Q4 | $3.32M | Buy |
3,221,012
+660,756
| +26% | +$711K | ﹤0.01% | 3203 |
|
|
2024
Q3 | $3.02M | Buy |
2,560,256
+714,853
| +39% | +$908K | ﹤0.01% | 3307 |
|
|
2024
Q2 | $2.25M | Buy |
1,845,403
+1,173,775
| +175% | +$2.34M | ﹤0.01% | 3440 |
|
|
2024
Q1 | $1.46M | Sell |
671,628
-122,419
| -15% | -$226K | ﹤0.01% | 3997 |
|
|
2023
Q4 | $1.23M | Buy |
794,047
+95,141
| +14% | +$125K | ﹤0.01% | 3990 |
|
|
2023
Q3 | $902K | Buy |
698,906
+49,608
| +8% | +$78.1K | ﹤0.01% | 4256 |
|
|
2023
Q2 | $1.12M | Sell |
649,298
-311,744
| -32% | -$518K | ﹤0.01% | 3959 |
|
|
2023
Q1 | $1.45M | Sell |
961,042
-758,769
| -44% | -$1.71M | ﹤0.01% | 3743 |
|
|
2022
Q4 | $2.75M | Buy |
1,719,811
+1,187,298
| +223% | +$1.76M | ﹤0.01% | 3293 |
|
|
2022
Q3 | $772K | Sell |
532,513
-909,219
| -63% | -$1.4M | ﹤0.01% | 4561 |
|
|
2022
Q2 | $2.64M | Sell |
1,441,732
-803,458
| -36% | -$1.54M | ﹤0.01% | 3421 |
|
|
2022
Q1 | $6M | Buy |
2,245,190
+978,268
| +77% | +$3.76M | ﹤0.01% | 2731 |
|
|
2021
Q4 | $5.49M | Buy |
1,266,922
+330,074
| +35% | +$1.93M | ﹤0.01% | 2806 |
|
|
2021
Q3 | $4.77M | Buy |
936,848
+340,519
| +57% | +$1.82M | ﹤0.01% | 2916 |
|
|
2021
Q2 | $3.77M | Buy |
596,329
+123,087
| +26% | +$958K | ﹤0.01% | 3125 |
|
|
2021
Q1 | $3.66M | Buy |
473,242
+110,581
| +30% | +$875K | ﹤0.01% | 2927 |
|
|
2020
Q4 | $2.38M | Buy |
362,661
+66,047
| +22% | +$472K | ﹤0.01% | 3107 |
|
|
2020
Q3 | $1.97K | Buy |
296,614
+190,592
| +180% | +$1.41M | ﹤0.01% | 2609 |
|
|
2020
Q2 | $883K | Sell |
106,022
-188,291
| -64% | -$1.75M | ﹤0.01% | 3058 |
|
|
2020
Q1 | $2.26M | Sell |
294,313
-29,669
| -9% | -$207K | 0.01% | 1933 |
|
|
2019
Q4 | $2.69M | Buy |
323,982
+260,709
| +412% | +$1.76M | ﹤0.01% | 2417 |
|
|
2019
Q3 | $466K | Sell |
63,273
-411,565
| -87% | -$4.06M | ﹤0.01% | 3309 |
|
|
2019
Q2 | $5.33M | Buy |
474,838
+384,901
| +428% | +$4.04M | 0.01% | 1719 |
|
|
2019
Q1 | $967K | Sell |
89,937
-68,501
| -43% | -$1.01M | ﹤0.01% | 2885 |
|
|
2018
Q4 | $2.39M | Sell |
158,438
-59,053
| -27% | -$876K | ﹤0.01% | 2092 |
|
|
2018
Q3 | $4.02M | Sell |
217,491
-47,430
| -18% | -$1.08M | ﹤0.01% | 1961 |
|
|
2018
Q2 | $6.06M | Sell |
264,921
-329,867
| -55% | -$8.43M | 0.01% | 1673 |
|
|
2018
Q1 | $16.9M | Sell |
594,788
-242,627
| -29% | -$6.92M | 0.02% | 982 |
|
|
2017
Q4 | $17.7M | Buy |
837,415
+212,423
| +34% | +$4.4M | 0.02% | 980 |
|
|
2017
Q3 | $11.4M | Buy |
624,992
+522,495
| +510% | +$8.15M | 0.02% | 1164 |
|
|
2017
Q2 | $1.59M | Sell |
102,497
-65,193
| -39% | -$983K | ﹤0.01% | 2205 |
|
|
2017
Q1 | $2.9M | Buy |
167,690
+114,220
| +214% | +$1.5M | 0.01% | 1783 |
|
|
2016
Q4 | $588K | Buy |
+53,470
| New | +$648K | ﹤0.01% | 2604 |
|
|
2016
Q3 | – | Sell |
-14,195
| Closed | -$145K | – | 3303 |
|
|
2016
Q2 | $145K | Buy |
+14,195
| New | +$162K | ﹤0.01% | 2966 |
|
Other funds holding CTMX
KCM
PA
VA
VCM
Millennium Management's CTMX Position: Q1 2026 in Review
Millennium Management increased its CytomX Therapeutics (CTMX) stake by 1,164% in Q1 2026, buying an estimated $17.1M and bringing the position to 3,660,190 shares worth $17.2M. The position accounts for 0.01% of the portfolio, ranked #1673.
Millennium Management first reported a position in CTMX in Q2 2016 and has held it in 39 quarters since. The position peaked at $17.7M in Q4 2017. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.
- Millennium Management held 3,660,190 shares of CytomX Therapeutics worth $17.2M as of Q1 2026.
- Millennium Management bought 3,370,537 CytomX Therapeutics shares in Q1 2026, an estimated $17.1M.
- CytomX Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1673 holding.
- Millennium Management first reported a position in CytomX Therapeutics in Q2 2016 and has held it in 39 quarters since.
- Millennium Management's CytomX Therapeutics position peaked at $17.7M in Q4 2017.
- 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.